Clinical Trial Update: A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial comparing CP-526,555 with placebo and Zyban (bupropion) for smoking cessation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence

Drugs mentioned

• CP-526,555
• Zyban (bupropion)

Snippet

Sponsor: Pfizer | Conditions: Smoking Cessation | Phase 2 | Status: COMPLETED